FLETCHER R JOHN 4

What Happened

• Fletcher R. John, a director of ClearPoint Neuro, was granted 12,820 restricted stock units (RSUs) on 2026-05-21. The grant is reported as an award (derivative acquisition) at $0.00 per unit — this is a compensation award, not a purchase or sale. Each RSU represents a contingent right to receive one share of CLPT common stock upon vesting.

Key Details

• Transaction date: 2026-05-21 (reported on Form 4 filed 2026-05-26).
• Grant: 12,820 RSUs; reported acquisition price $0.00 (award/derivative).
• Vesting: RSUs vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company’s 2027 annual meeting of stockholders.
• Shares owned after transaction: not specified in the filing.
• Filing timing: Form 4 was filed five days after the reported grant date; Form 4s are generally due within two business days, so this filing appears later than the usual reporting window.

Context

• RSU grants are common compensation for directors and are not direct purchases or sales; they become shares only upon vesting and any subsequent delivery/sale would be reported separately. Because the award was granted at $0.00, no cash changed hands for this grant itself. To estimate the grant’s market value, multiply 12,820 by CLPT’s share price on the grant date.